Search - tctmd.com

Displaying 141 - 160 of 381

Sort: Relevancy | Date

News Daily News

In COVID-19 Patients, Vaccination Linked to Lower MACE Risk

Michael O'Riordan

February 22, 2023

News Daily News

Erectile Dysfunction Drugs Show Cardioprotective Effects in Low-risk Men

Yael L. Maxwell

February 21, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

News Daily News

Maternal CV Risk After Adverse Pregnancy Outcome Can Last Over 40 Years

L.A. McKeown

February 13, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Daily News

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Todd Neale

January 18, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Opinion CV Team Dispatch

December 2022 News Roundup

L.A. McKeown

December 28, 2022

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Todd Neale

November 05, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Opinion CV Team Dispatch

November 2022 News Roundup

L.A. McKeown

November 01, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

News Opinion CV Team Dispatch

October 2022 News Roundup

L.A. McKeown

October 01, 2022

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Advertisement

In COVID-19 Patients, Vaccination Linked to Lower MACE Risk

Erectile Dysfunction Drugs Show Cardioprotective Effects in Low-risk Men

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Maternal CV Risk After Adverse Pregnancy Outcome Can Last Over 40 Years

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

December 2022 News Roundup

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

November 2022 News Roundup

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

October 2022 News Roundup

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content